Articles

The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone. Read More ›

Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance. Read More ›

Updated results from the IKEMA trial show a superior benefit with isatuximab + carfilzomib and dexamethasone versus carfilzomib and dexamethasone alone in patients with RRMM. Read More ›

Cohort B of CARTITUDE-2 evaluated the safety and efficacy of cilta-cel in high-risk patients who experienced early clinical relapse to determine its use in earlier lines of therapy. Read More ›

A discrete-choice experiment and best-worst scaling survey identified the most and least important multiple myeloma treatment characteristics to patients and their caregivers. Read More ›

Long-term outcomes from MAIA support the use of daratumumab plus lenalidomide and dexamethasone for ≥18 months in newly diagnosed, transplant ineligible MM patients. Read More ›

Final analysis of ICARIA-MM demonstrated a 6.9-month improvement in survival with Isa-Pd compared to Pd alone in RRMM patients. Read More ›

Meta-analysis of whole-body MRI versus FDG PET/CT to assess treatment response in MM may suggest a complementary benefit when utilizing both modalities. Read More ›

Updated phase 2 results of the MonumenTAL-1 study showed promising efficacy and a tolerable safety profile with talquetamab, a novel T-cell–redirecting bispecific antibody, in patients with RRMM. Read More ›

Real-world analysis of patients with MM determines treatment patterns and survival outcomes in patients with t(11;14) compared to patients with high- and standard-risk cytogenetics. Read More ›